Proposed Information Collection Activity; Comment Request, 39244-39245 [2012-16029]
Download as PDF
<![CDATA[
39244
Federal Register / Vol. 77, No. 127 / Monday, July 2, 2012 / Notices
clarity of the information to be
collected; and (d) ways to minimize the
burden of the information collection on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
All comments will become a matter of
public record.
Dated at Washington, DC, this 26th day of
June 2012.
Federal Deposit Insurance Corporation.
Robert E. Feldman,
Executive Secretary.
[FR Doc. 2012–16030 Filed 6–29–12; 8:45 am]
BILLING CODE 6714–01–P
FEDERAL RESERVE SYSTEM
mstockstill on DSK4VPTVN1PROD with NOTICES
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than July 17,
2012.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. Sidney J. Lee, as an individual, and
together with Medora Lee, both of
Chicago, Illinois, and Serena Lee,
Greenwich, Connecticut; as a group
acting in concert to acquire control of
American Metro Bancorp, Inc., and
thereby indirectly acquire control of
American Metro Bank, both in Chicago,
Illinois.
Board of Governors of the Federal Reserve
System, June 27, 2012.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2012–16122 Filed 6–29–12; 8:45 am]
BILLING CODE 6210–01–P
VerDate Mar<15>2010
17:22 Jun 29, 2012
Jkt 226001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Office for State, Tribal, Local and
Territorial Support (OSTLTS); Meeting
In accordance with Presidential
Executive Order No. 13175, November
6, 2000, and the Presidential
Memorandum of November 5, 2009 and
September 23, 2004, Consultation and
Coordination with Indian Tribal
Governments, CDC and the Agency for
Toxic Substances and Disease Registry
(ATSDR) announces the following
meeting and Tribal Consultation
Session:
Name: Tribal Advisory Committee (TAC)
Meeting and 9th Biannual Tribal
Consultation Session.
Times and Dates:
8:00 a.m.–5:00 p.m., August 28 and 29,
2012 (TAC Meeting);
8:00 a.m.–4:00 p.m., August 30, 2012 (9th
Biannual Tribal Consultation Session).
Place: The TAC Meeting will be held at the
Mohegan Sun, 1 Mohegan Sun Boulevard,
Uncasville, Connecticut 06382.
Status: The meetings are being hosted by
CDC/ATSDR and the Mohegan Tribe and are
open to the public.
Purpose: The purpose of the Biannual
Tribal Consultation is for CDC/ATSDR
leadership and staff to conduct governmentto-government consultation with elected
tribal officials or their designated
representatives and confer with American
Indian/Alaska Native (AI/AN) communitybased organizations and AI/AN urban and
rural communities on issues that affect them.
This exchange of information is meant to
increase mutual understanding and increase
effective collaboration and informed decision
making. The purpose of the CDC/ATSDR
Tribal Advisory Committee or TAC is to
provide a complementary venue wherein
tribal representatives and CDC/ATSDR
leadership and staff exchange information
about public health issues in Indian Country,
identify urgent public health needs in AI/AN
communities, and discuss collaborative
approaches to addressing these issues and
needs.
Matters To Be Discussed: The following
topics are scheduled for presentation and
discussion during the TAC Meeting;
however, discussion is not limited to these
topics: Social determinants of health, cancer
control and prevention, the Strategic
National Stockpile (strategically placed
medicine and supplies for use in national
emergencies) and opportunities at CDC/
ATSDR for Native participation.
Topics that will be discussed during the
Tribal Consultation include the following:
Controlled Substance Abuse, Tobacco
Control Efforts, and Motor Vehicle Safety.
Additional opportunities will be provided
during the Consultation Session for tribal
testimony. Tribal Leaders are encouraged to
submit written testimony by 12:00 a.m., EST
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
on August 22, 2012, to Kimberly Cantrell,
Deputy Associate Director for Tribal Support,
OSTLTS, CDC, via mail to 1600 Clifton Road
NE., MS K–70, Atlanta, Georgia 30329, or
email to klw6@cdc.gov. Depending on the
time available, it may be necessary to limit
the time of each presenter.
The agenda is subject to change as
priorities dictate.
Information about the two upcoming
meetings, past meetings, and CDC/ATSDR’s
policies related to these meetings, are
available at https://www.cdc.gov/
stltpublichealth/TribalSupport/
announcements.html.
Contact Person for More Information:
Kimberly Cantrell, Deputy Associate Director
for Tribal Support, OSTLTS, CDC, via mail
to 1600 Clifton Road NE., MS K–70, Atlanta,
Georgia 30329, or email to klw6@cdc.gov.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Dated: June 22, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–16097 Filed 6–29–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request
Proposed Projects:
Title: National Medical Support
Notice—NPRM.
OMB No.: 0970–0222.
Description: The National Medical
Support Notice (NMSN) is a two-part
document to be completed by state child
support enforcement agencies,
employers, and health plan
administrators to assist in enforcing
health care coverage provisions in a
child support order. The Department of
Health and Human Services (HHS)
developed and maintains Part A of the
NMSN, which is sent to an obligor’s
employer for completion; the
Department of Labor (DOL) developed
and maintains Part B of the NMSN,
which is provided to health care
administrators following completion of
Part A.
DOL revised Part B to conform with
changes to the currently approved Part
A and is seeking a three year approval
from the Office of Management and
Budget (OMB). To avoid burdening the
E:\FR\FM\02JYN1.SGM
02JYN1
39245
Federal Register / Vol. 77, No. 127 / Monday, July 2, 2012 / Notices
state child support enforcement
agencies with potential reprogramming
at varying times due to future changes
in either Part A or Part B, the
Administration for Children and
Families is resubmitting an unchanged
information collection package and
requesting an extension to the current
OMB approval of NMSN Part A to
synchronize with the expiration date of
NMSN Part B.
Respondents: State child support
enforcement agencies, employers, and
health plan administrators.
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
National Medical Support Notice .....................................................................
54
97,775
0.17
897,574.50
mstockstill on DSK4VPTVN1PROD with NOTICES
Estimated Total Annual Burden
Hours: 897,574.50.
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: ACF Reports Clearance Officer.
Email address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2012–16029 Filed 6–29–12; 8:45 am]
BILLING CODE 4184–01–P
VerDate Mar<15>2010
17:22 Jun 29, 2012
Jkt 226001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0063]
Sami Arshak Yanikian: Debarment
Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) debarring
Sami Arshak Yanikian for 10 years from
providing services in any capacity to a
person that has an approved or pending
drug product application. FDA bases
this order on a finding that Mr. Yanikian
was convicted of two counts of
introducing unapproved new drugs into
interstate commerce, which relates to
the development or approval, including
the process for development or
approval, of drug products and to the
regulation of drug products under the
FD&C Act. In addition, the type of
conduct that served as the basis for Mr.
Yanikian’s convictions undermine the
process for the regulation of drugs. Mr.
Yanikian was given notice of the
proposed debarment and an opportunity
to request a hearing within the
timeframe prescribed by regulation. Mr.
Yanikian failed to respond. Mr.
Yanikian’s failure to respond constitutes
a waiver of his right to a hearing
concerning this action.
DATES: This order is effective July 2,
2012.
ADDRESSES: Submit applications for
termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Kenny Shade, Office of Regulatory
Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD
20857, 301–796–4640.
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(2)(B)(i)(I) of the FD&C
Act (21 U.S.C. 335a(b)(2)(B)(i)(I))
permits FDA to debar an individual if it
finds that the individual has been
convicted of a misdemeanor under
Federal law for conduct relating to the
development or approval, including the
process for development or approval, of
any drug product or otherwise relating
to the regulation of drug products under
the FD&C Act, and if FDA finds that the
type of conduct that served as the basis
for the conviction undermines the
process for the regulation of drugs.
On June 29, 2011, Mr. Yanikian was
found guilty of two counts of
introduction of an unapproved drug in
interstate commerce, in violation of
sections 301(d), 505(a), and 303(a)(1) of
the FD&C Act (21 U.S.C. 331(d), 355(a),
333(a)(1)) and of aiding and abetting, in
violation of 18 U.S.C. 2(b), and the U.S.
District Court for the Central District of
California entered judgment against Mr.
Yanikian for the misdemeanor offenses
of introduction of an unapproved drug
in interstate commerce and aiding and
abetting.
The FDA’s finding that debarment is
appropriate is based on the
misdemeanor convictions referenced
herein. The factual basis for the
conviction is as follows: On March 17,
2005, FDA sent Mr. Yanikian a warning
letter regarding his marketing and sale
of Novel natural formulation for atrial
fibrillation, Super Nasal Drops, and
Sams No Tinnitus Formulation. The
warning letter described the claims Mr.
Yanikian’s Web site was making
pertaining to these products and
informed him that his claims caused the
products to be ‘‘drugs’’ as defined by the
FD&C Act because they were intended
to cure, mitigate, treat, or prevent
disease. Mr. Yanikian was informed that
his products were ‘‘new drugs’’ and that
a new drug could not be introduced or
delivered for introduction into interstate
commerce unless an FDA-approved
application was in effect for it. The
E:\FR\FM\02JYN1.SGM
02JYN1
]]>Agencies
[Federal Register Volume 77, Number 127 (Monday, July 2, 2012)]
[Notices]
[Pages 39244-39245]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-16029]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Proposed Information Collection Activity; Comment Request
Proposed Projects:
Title: National Medical Support Notice--NPRM.
OMB No.: 0970-0222.
Description: The National Medical Support Notice (NMSN) is a two-
part document to be completed by state child support enforcement
agencies, employers, and health plan administrators to assist in
enforcing health care coverage provisions in a child support order. The
Department of Health and Human Services (HHS) developed and maintains
Part A of the NMSN, which is sent to an obligor's employer for
completion; the Department of Labor (DOL) developed and maintains Part
B of the NMSN, which is provided to health care administrators
following completion of Part A.
DOL revised Part B to conform with changes to the currently
approved Part A and is seeking a three year approval from the Office of
Management and Budget (OMB). To avoid burdening the
[[Page 39245]]
state child support enforcement agencies with potential reprogramming
at varying times due to future changes in either Part A or Part B, the
Administration for Children and Families is resubmitting an unchanged
information collection package and requesting an extension to the
current OMB approval of NMSN Part A to synchronize with the expiration
date of NMSN Part B.
Respondents: State child support enforcement agencies, employers,
and health plan administrators.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Instrument Number of responses per hours per Total burden
respondents respondent response hours
----------------------------------------------------------------------------------------------------------------
National Medical Support Notice............. 54 97,775 0.17 897,574.50
----------------------------------------------------------------------------------------------------------------
Estimated Total Annual Burden Hours: 897,574.50.
In compliance with the requirements of Section 506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the Administration for Children and
Families is soliciting public comment on the specific aspects of the
information collection described above. Copies of the proposed
collection of information can be obtained and comments may be forwarded
by writing to the Administration for Children and Families, Office of
Planning, Research and Evaluation, 370 L'Enfant Promenade SW.,
Washington, DC 20447, Attn: ACF Reports Clearance Officer. Email
address: infocollection@acf.hhs.gov. All requests should be identified
by the title of the information collection.
The Department specifically requests comments on: (a) Whether the
proposed collection of information is necessary for the proper
performance of the functions of the agency, including whether the
information shall have practical utility; (b) the accuracy of the
agency's estimate of the burden of the proposed collection of
information; (c) the quality, utility, and clarity of the information
to be collected; and (d) ways to minimize the burden information to be
collected; and (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology.
Consideration will be given to comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2012-16029 Filed 6-29-12; 8:45 am]
BILLING CODE 4184-01-P
